ACTA1 and systemic sclerosis: Considering salirasib significantly reduced the expression of genes related to the fibrosis process and α‐SMA gene and protein expression, and given significant upregulation of MMP1 by salirasib, it can be considered as a new curative strategy for fibrotic diseases like SSc.